Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 21;10(7):1083.
doi: 10.3390/biom10071083.

Sphingolipid Analysis Indicate Lactosylceramide as a Potential Biomarker of Inflammatory Bowel Disease in Children

Aleksandra Filimoniuk  1 , Agnieszka Blachnio-Zabielska  2 , Monika Imierska  2 , Dariusz Marek Lebensztejn  1 , Urszula Daniluk  1
Affiliations

Sphingolipid Analysis Indicate Lactosylceramide as a Potential Biomarker of Inflammatory Bowel Disease in Children

Aleksandra Filimoniuk et al. Biomolecules. .

Abstract

An altered ceramide composition in patients with inflammatory bowel disease (IBD) has been reported recently. The aim of this study was to evaluate the concentrations of sphingolipids in the serum of treatment-naive children with newly diagnosed IBD and to determine the diagnostic value of the tested lipids in pediatric IBD. The concentrations of sphingolipids in serum samples were evaluated using a quantitative method, an ultra-high-performance liquid chromatography-tandem mass spectrometry in children with Crohn's disease (CD) (n=34), ulcerative colitis (UC) (n = 39), and controls (Ctr) (n = 24). Among the study groups, the most significant differences in concentrations were noted for C16:0-LacCer, especially in children with CD compared to Ctr or even to UC. Additionally, the relevant increase in C20:0-Cer and C18:1-Cer concentrations were detected in both IBD groups compared to Ctr. The enhanced C24:0-Cer level was observed only in UC, while C18:0-Cer only in the CD group. The highest area under the curve (AUC), specificity, and sensitivity were determined for C16:0-LacCer in CD diagnosis. Our results suggest that the serum LacC16-Cer may be a potential biomarker that distinguishes children with IBD from healthy controls and differentiates IBD subtypes. In addition, C20:0-Cer and C18:0-Cer levels also seem to be closely connected with IBD.

Keywords: Crohn’s disease; ceramide; children; inflammatory bowel disease; lactosylceramide; sphingolipid; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The overview of sphingolipid metabolism. SPT: serine palmitoyltransferase, CerS: ceramide synthase, dhCer desaturase: dihydroceramide desaturase, S1PP: sphingosine-1-phosphate phosphatase, SPHK: sphingosine kinase, SPL: sphingosine-1-phosphate lyase, CDase: ceramidase, SMase: sphingomyelinase, SM synthase: sphingomyelinase synthase, GCS: glucosyl-ceramide synthase.
Figure 2
Figure 2
Serum concentrations of sphingolipids in children with Crohn’s disease (CD), ulcerative colitis (UC), and the control group (Ctr). The statistical difference was analyzed by the Mann–Whitney U test. p values <0.05 were considered significant. (* p < 0.05, ** p < 0.01, *** p < 0.001).
See this image and copyright information in PMC

References

    1. Levine A., Koletzko S., Turner D., Escher J.C., Cucchiara S., de Ridder L., Kolho K.L., Veres G., Russell R.K., Paerregaard A., et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 2014;58:795–806. doi: 10.1097/MPG.0000000000000239. - DOI - PubMed
    1. Daniluk U., Daniluk J., Krasnodebska M., Lotowska J.M., Sobaniec-Lotowska M.E., Lebensztejn D.M. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn’s disease. Adv. Med. Sci. 2019;64:9–14. doi: 10.1016/j.advms.2018.08.001. - DOI - PubMed
    1. Daniluk U., Daniluk J., Kucharski R., Kowalczyk T., Pietrowska K., Samczuk P., Filimoniuk A., Kretowski A., Lebensztejn D., Ciborowski M. Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn’s Disease and Ulcerative Colitis-A Preliminary Study. Inflamm. Bowel. Dis. 2019;25:1120–1128. doi: 10.1093/ibd/izy402. - DOI - PubMed
    1. Bazarganipour S., Hausmann J., Oertel S., El-Hindi K., Brachtendorf S., Blumenstein I., Kubesch A., Sprinzl K., Birod K., Hahnefeld L., et al. The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent.Regulated. J. Clin. Med. 2019;8:971. doi: 10.3390/jcm8070971. - DOI - PMC - PubMed
    1. Diab J., Hansen T., Goll R., Stenlund H., Ahnlund M., Jensen E., Moritz T., Florholmen J., Forsdahl G. Lipidomics in Ulcerative Colitis Reveal Alteration in Mucosal Lipid Composition Associated with the Disease State. Inflamm. Bowel Dis. 2019;25:1780–1787. doi: 10.1093/ibd/izz098. - DOI - PubMed

Publication types

LinkOut - more resources